GOP lawmaker seeks to ban billboards advertising medical marijuana

The way Sen. David Farnsworth sees it, the decision by voters to legalize the sale of marijuana for medical uses does not mean they get to promote it.

So the Mesa Republican has introduced legislation which would ban billboard advertising for the drug in places they’re most likely to be seen. SB 1032 would make it illegal to advertise any drug illegal under federal law — and that includes marijuana — along state roads.

Whether that’s legal or not is up for debate.

Attorney Jeff Kaufman who has specialized in legal issues surrounding marijuana questioned whether the state could enact special rules for a product that is legal, at least under state law. He pointed out that judges in Arizona have said the state can’t use the federal prohibition as a reason to enact regulations that hamper the ability of marijuana dispensaries to operate.

“I think the bill, if enacted, would eventually be stricken down by the Court of Appeals as discriminating against a lawful form of medication,” Kaufman said.

Dan Barr, a lawyer with the First Amendment Coalition, sees it in a slightly different light.

He said that courts have given governments a certain amount of leeway in regulating “commercial speech.” For example, Barr noted, California has rules that prohibit advertising in a manner intended to encourage anyone under 21 from consuming the product and a strict ban on billboards within 1,000 feet of day-care centers and schools.

Kaufman and Barr agree that Farnsworth cannot legally do one of the things he wants: making it illegal to have signs touting the benefits of the drug or making claims about how legalization has worked out in other states.

That clearly is one of Farnsworth’s goals.

He specifically complained to Capitol Media Services about a billboard he saw which says

Read More Here...

Superfund Priorities | Downtown Crime | Medical Marijuana

By Allison Frost, Sage Van Wing, Samantha Matsumoto 1 hour ago

View Slideshow 1 of 2

View Slideshow 2 of 2

Washington Post environmental reporter Brady Dennis joins us to talk about the Environmental Protection Agency’s recently released list of  Superfund “priority” sites where it says it wants to expedite the cleanup. We find out what this could mean for the Willamette River Superfund site in Portland, and more about how the agency is being run under the direction of one of its biggest critics, Scott Pruitt.

Last week we heard from Columbia CEO Tim Boyle, who says increased crime in downtown Portland has become untenable for his employees. For another business perspective on this, we hear from Ashley Henry of Business For A Better Portland.

After the legalization of recreational marijuana, most medical dispensaries in the state have switched over to the recreational market. Dispensary owners had a deadline on Dec. 1 to notify the Oregon Health Authority whether they intended to switch to the recreational industry. Of the 16 medical dispensaries remaining in the state, several have indicated they plan to become recreational sellers. We’ll talk about how this affects the medical marijuana program with a medical dispensary manager, a recreational dispensary founder, medical marijuana advocate and the Oregon Liquor Control Commission.

Read More Here...

First mid-Alameda County medical cannabis product maker gets OK

SAN LEANDRO —  The first manufacturing facility for a medical marijuana product in mid-Alameda County is well on its way to opening its doors by next year.

The San Leandro Board of Zoning Adjustments, by a 4-0 vote, has approved plans for Dispersa Labs, of Tarpon Springs, Florida, to build a 7,745-square-foot warehouse at 1655 Abram Court, where a dry cannabis powder inhaler for medical uses will be manufactured.

“We’re a startup and very excited about the opportunity to go in (here),” Dispersa Labs co-founder David Cookson said at the Dec. 7 meeting.

“We’re making a very technical product — it’s a very low impact use — and we think it’s an opportunity for us and the city of San Leandro to explore cannabis in the best possible way and advance the trade,” he said.

Zoning board members Catherine Vierra Houston and Marguerite Mazzitti were absent.

The City Council in July approved creating a pilot program allowing up to five cannabis product manufacturers to operate in some San Leandro industrial areas.

Applications for businesses that manufacture cannabis products in San Leandro are considered on a case-by-case basis and do not require buffer zones away from schools, day care centers and youth centers.

Dispersa Labs has been the only applicant to apply to manufacture cannabis products under San Leandro’s pilot program, city planning manager Andrew Mogensen said. Part of the problem, he said, is that there aren’t many vacant spaces in the city’s industrial area for any business.

“If you’re a cannabis business, it’s even more difficult because a lot of real estate investment trusts and other businesses will not allow them to lease their property, so it has been very difficult for cannabis manufacturers to find locations in our city,” Mogensen said at the meeting.

“We do expect to see more applications in the future,

Read More Here...

Research lacking on benefits of medical marijuana: doctors' groups

There is little to no research to support the supposed benefits of medical cannabis, and what evidence exists suggests that using marijuana as medicine may do more harm than good, family doctors’ associations across Canada are telling their members.

A trio of advisories prepared by the Alberta College of Family Physicians has been distributed to more than 32,000 clinicians, summarizing the scientific literature, or lack thereof, around medicinal marijuana.

“One thing that was quite consistent was adverse events,” said Dr. Mike Allan, a professor of family medicine at the University of Alberta in Edmonton. “And the benefits, even if they’re real, are much smaller than what people might anticipate.”

Story continues below advertisement

Allan co-ordinates the college’s biweekly updates, “Tools for Practice,” which focus on topical issues and are circulated through professional chapters in every province except Quebec and Newfoundland and Labrador.

The three most recent updates were inspired by physicians wanting to know more about the research behind medical cannabis. Family doctors are facing increasing pressure from patients asking about medicinal pot and the college wants to ensure its members have the information they need to make informed decisions around treatment, Allan said.

“I think this gives (doctors) some comfort, saying, ‘Look, here’s the evidence. It’s actually missing in a lot of places, so I can’t give it for conditions X, Y and Z,’ ” Allan said. He described medical pot as a high-risk product that should only used in rare circumstances when other, safer treatment options have been exhausted.

Health Canada data show the number of clients registered with licensed medical marijuana producers jumped to more than 200,000 as of June 2017, which is about 2.7 times greater than the 75,166 people registered at the same time last year. Registrations

Read More Here...

Medical marijuana has NO public health risks and should not be withheld from patients, WHO declares after months of …

The WHO has declared medical marijuana is beneficial for cancer, epilepsy, Alzheimer’s, Parkinson’s and other diseasesThe organization found the drug is not addictive and holds no public health risks 

The World Health Organization has declared that CBD – the relaxant property of cannabis used in medical marijuana – should not be a scheduled drug.  

As legalization of cannabis has spread rapidly across the United States and around the world, health officials have cautioned that we do not have enough research to rule out any down sides.  

But today, after months of deliberation and investigation, the WHO has concluded that cannabidiol (CBD) is a useful treatment for epilepsy and palliative care, and does not carry any addiction risks. 

While the organization is set to run a fuller review of cannabis next year, assessing all cannabis-related substances, physicians and the cannabis industry have been poised awaiting this decision to deny scheduling for months.

Had the WHO chosen to schedule the drug, it could have hamstrung physicians from prescribing medical marijuana globally.   

The WHO has declared medical marijuana is beneficial for cancer, epilepsy, Alzheimer’s, Parkinson’s and other diseases, and does not carry an addiction risk

The report, published today, also recommended imposing the strong restrictions available on fentanyl, a synthetic opioid which has killed thousands of people in America’s drug addiction epidemic.    

‘There is increased interest from Member States in the use of cannabis for medical indications including for palliative care,’ the report said. 

‘Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components.’

In conclusion, the authors wrote: ‘Recent evidence

Read More Here...